ArticleBMC cancer2025
Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the efficacy of lenvatinib combined with either radiotherapy (RT) or transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC).
methodsConducted between December 2018 and January 2022, this retrospective study included 32 patients with advanced HCC from a single institution. The patients were divided into two treatment groups: RT plus lenvatinib (n = 17) and TACE plus lenvatinib (n = 15). The primary outcomes assessed were overall survival (OS) and infield control (IFC). Treatment modalities, patient demographics, disease characteristics, and therapeutic responses were analyzed using the Kaplan-Meier method and Cox regression models to identify predictors of OS and IFC. To address baseline imbalances and competing risks, inverse-probability-of-treatment weighting (IPTW) and Fine-Gray analyses were applied to better estimate IFC outcomes.
resultsWith a median follow-up of 10.2 months, no significant difference in OS was observed between the RT and TACE groups. However, the Kaplan-Meier analysis indicated significantly longer IFC durations in the RT group (p = 0.010), with a 1-year IFC rate of 74.7% compared to 13.2% in the TACE group. Multivariable analysis further demonstrated that the RT group was associated with better IFC outcomes (p = 0.023). After IPTW adjustment, the RT group retained a significant IFC benefit (p = 0.020). At 12 months, the cumulative infield failure rate was 61.0% in the TACE group versus 14.9% in the RT group (p = 0.015). Alpha-fetoprotein levels significantly declined within 3 months after RT (p = 0.002) but not after TACE (p = 0.510). A ≥ 2-point deterioration in the Child-Pugh score was observed in 5.9% of the RT group when compared to 26.7% of the TACE group (p = 0.161).
conclusionThese findings suggest that RT combined with lenvatinib may offer advantages in local tumor control and potentially liver function preservation, providing a promising alternative for patients with advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.